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B than in group A (p  ! 0.05, for all parameters). At the 
start of therapy, in both groups of patients percentage 
FM was higher and total and leg LTM lower than in con-
trols (p  ! 0.05 for each parameter). Thereafter, FM de-
creased and LTM increased and after 2 years they were 
both different from baseline (p  ! 0.05). After 2 years of 
treatment, leg BMC and BMD were more positively cor-
related with regional leg LTM in patients of group B (r = 
0.834 and r = 0.827, respectively; p  ! 0.001) than in pa-
tients of group A (r = 0.617 and r = 0.637, respectively; 
p  ! 0.05). 25-OHD and PTH levels were in the normal 
range in all patients at the start and during treatment. OC 
levels were lower and urinary NTx levels higher in pa-
tients than in controls (p  ! 0.05 for both parameters), 
either at the start and after 1 year of treatment. After 2 
years of treatment, OC levels were signifi cantly higher 
than at the start of the study (p  ! 0.05) in both groups of 
patients, but they were higher in group B than in group 
A (p  ! 0.05); on the contrary, urinary Ntx levels were 
lower in group B than in group A (p  ! 0.05).  Conclusion: 
In GHD children, treated with GH, calcium supplementa-
tion improved bone mass; it may aid in reaching better 
peak bone mass and in protecting weight-bearing bones, 
usually completed in childhood to maximum levels, 
from risk of osteoporosis and fractures later in life. 
 Copyright © 2006 S. Karger AG, Basel 
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 Abstract 
 Background/aims: Since GH plays an important role in 
bone mineralization, and several studies demonstrated 
the positive infl uence of a higher calcium intake on bone 
mass, we studied the effect of calcium supplementation 
in GHD children during GH therapy.  Methods: 28 prepu-
bertal GHD children, 5.0–9.9 years old, were assigned to 
two groups: group A (n = 14; 7 females) treated with GH, 
and group B (n = 14; 7 females) treated with GH + calcium 
gluconolactate and carbonate (1 g calcium/day per os). 
Auxological parameters, total bone mineral content 
(TBMC) and density (TBMD), leg BMC and BMD, lumbar 
BMD, fat mass (FM) and lean tissue mass (LTM), blood 
25-hydroxyvitamin D (25-OHD), parathyroid hormone 
(PTH), osteocalcin (OC) and urinary N-terminal telopep-
tide of type I collagen (NTx) were determined at the start 
of therapy and after 1 and 2 years of treatment.  Results: 
During the 2 years of the study, TBMC, TBMD, leg BMC 
and BMD (but not lumbar BMD) increased in both groups 
of patients, however after 2 years of treatment they were 
signifi cantly higher in the calcium-supplemented group 
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 Introduction 
 It is well known that growth hormone-deﬁ cient (GHD) 
children have reduced bone mineral density (BMD), be-
cause of delayed bone maturation and absence of GH 
anabolic actions on bone  [1] . GH therapy improves BMD 
 [2] , however childhood-onset GHD patients have an in-
creased susceptibility to osteoporosis, with its attendant 
risks of fragility fracture later in life. In fact, peak bone 
mass (PBM) occurs several years after the completion of 
linear growth, in late adolescence and early adulthood, 
and the discontinuation of GH therapy at the completion 
of linear growth could limit the attainment of PBM  [3, 4] . 
Therefore, the GHD patients not adequately treated 
could not reach PBM at the time of discontinuation of 
GH therapy and could show a bone mineral mass lower 
than their genetic potential. Consequently, the normal-
ization of bone mass deﬁ cit represents a major advance 
in the prevention of osteoporosis and bone fractures  [5] . 
The variability in PBM is accounted for by genetic factors 
predominantly; however, even environmental inﬂ uences, 
as endocrine function, physical activity and nutrition, 
may affect the ability of an individual to reach the ge-
netic potential for bone mass  [6] , as well as interactions 
between environmental and genetic factors. 
 Concerning nutrition, randomized controlled studies 
demonstrated that calcium intake correlated with BMD 
in healthy adolescents  [7, 8] , that calcium supplementa-
tion above the recommended dietary allowances in-
creased BMD in prepubertal children  [9, 10] , that PBM 
was optimal when the threshold calcium balance was met 
 [11] and that calcium supplementation increased the 
bone mineral content (BMC) of children with habitually 
low calcium intake  [12] . In addition, we showed in previ-
ous studies that calcium supplementation improved bone 
mass in females affected by central precocious puberty 
and treated with GnRH agonists  [13, 14] . On these bases, 
the aim of the present longitudinal study was to deter-
mine whether calcium supplementation improved bone 
mass also in prepubertal GHD children treated with GH 
and supplemented with calcium. 
 Patients and Methods 
 Patients 
 Twenty-eight prepubertal Caucasian GHD children (14 fe-
males), 5.0–9.9 years old, took part in the study. The diagnosis of 
GHD was based on the following criteria: height  ! 2 SDS; bone age 
(BA) delay  1 2 years compared with chronological age (CA); GH 
peak  ! 10 ng/ml in at least two consecutive pharmacological tests; 
insulin-like growth factor I (IGF-I) levels below the mean of age- 
and sex-matched controls. None of the patients had organic GH 
deﬁ ciency or panhypopituitarism or multiple pituitary hormone 
deﬁ ciency, all being affected by idiopathic isolated GHD, as as-
sessed by full endocrine evaluation and magnetic resonance imag-
ing of the hypothalamic-pituitary and stalk-pituitary region. 
 Patients, at the start of treatment with recombinant GH at a 
dose of 0.033 mg/kg 6 days/week, were randomly assigned to two 
groups (A and B) comparable for sex, CA, BA, weight and height, 
using a computer pseudorandom number generator. Patients in 
group A (n = 14; 7 females) were treated solely with GH; patients 
in group B (n = 14; 7 females) received a treatment with GH plus 
supplementation of a commercial combination pill of calcium glu-
conolactate and carbonate (1 g calcium/day per os in two doses). 
 Height, weight, body mass index (BMI), total bone mineral con-
tent (TBMC) and density (TBMD), lumbar spine BMD and leg 
BMC and BMD, fat percentage (fat %) and total lean mass (kg), 
plasma 25-hydroxyvitamin D (25-OHD) and serum parathyroid 
hormone (PTH) levels, serum osteocalcin (OC) as marker of bone 
formation and urinary N-terminal telopeptide of type I collagen 
(NTx) as marker of bone resorption, urine calcium/creatinine ratio, 
were determined at the start of therapy and after 1 and 2 years of 
treatment. No patients received other drugs known to interfere with 
bone mineral metabolism. Renal and hepatic functions were nor-
mal. 
 All the subjects were instructed to continue their usual physical 
activity and diet, thereby ensuring adequate caloric (70–80 cal/kg/
day), protein ( 1 1 g/kg/day), calcium ( 1 800 mg/day), and phosphate 
( 1 800 mg/day) intake during treatment. Diet was investigated by a 
weighed food record and dietary calcium intake was determined by 
a detailed food frequency questionnaire of dairy products  [15] . 
Compliance in assumption of calcium supplementation was 
checked by a diary in patients of group B. Physical activity, includ-
ing physical education classes, organized sports, recreational activ-
ity, and habitual walking and cycling, was investigated by an exer-
cise diary and was measured in minutes per week  [16] . 
 At the start and after 1 and 2 years of treatment, auxological, 
body composition, and bone densitometric data of patients were 
compared with those of different control groups of the same CA, 
with BA appropriate for CA, and BMI between the 25th and 75th 
percentile  [17] ; they were composed of 26 (13 females), 24 (12 fe-
males) and 28 (14 females) children, at the start of the study and 
after 1 and 2 years, respectively. The inclusion criteria, at each time 
point of the study, were: age-matching with the patient population, 
white race, prepubertal stage and normal calcium intake. The ex-
clusion criteria were: a history of metabolic bone, kidney, liver, 
gastric and bowel disease; other systemic chronic disease, and use 
of medications known to affect bone metabolism. 
 Informed consent was obtained from all parents of study par-
ticipants and the study protocol was approved by our institutional 
ethics committee. 
 Methods 
 Weight was measured with minimal clothing and without shoes 
on a standard clinical balance. Standing height was measured by a 
Harpenden stadiometer. BMI was calculated as weight (kg)/height 
(m 2 ) and compared with age- and sex-matched reference values  [17] 
to calculate SD scores (SDs). BA evaluation was determined blind-
ly by the same expert observer according to the method of Greulich 
and Pyle  [18] and expressed in years. 
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 Plasma 25-OHD was measured by high-pressure liquid chroma-
tography (HPLC) (Eureka srl, Chiaravalle, Ancona, Italy). The in-
tra- and interassay coefﬁ cients of variations (CVs) were below 5.2 
and 7.8%, respectively. The sensitivity was 5 nmol/l. Serum intact 
1-84 PTH levels were determined by immunometric chemilumi-
nescence assay (Nichols Institute Diagnostics, San Clemente, Cal-
if., USA). The intra- and interassay CVs were below 6.7 and 9.2%, 
respectively. The sensitivity was 0.1 pmol/l. Serum OC was mea-
sured by immunometric chemiluminescence assay (Diagnostic 
Products Corp., Los Angeles, Calif., USA). The intra- and interas-
say CVs were below 4.5 and 7.1%, respectively. The sensitivity was 
0.02 nmol/l. Urine levels of NTx were measured by an enzyme im-
munosorbent assay (Osteomark; Ostex, Seattle, Wash., USA). 
Urine specimens were collected between 10:  00 and 12:  00 h as the 
second voiding of the day. Assay values were expressed in nano-
moles bone collagen equivalents per liter (nmol BCE/l). The sample 
results from a single urine collection were normalized for urine di-
lution by urine creatinine analysis and were reported as nmol BCE/
mmol creatinine. The intra- and interassay CVs were less than 9%. 
The sensitivity was 20 nmol BCE/l. Urine calcium and creatinine 
were analyzed using standard laboratory methods and were ex-
pressed as urine Ca/Cr ratio (  mol/mmol). 
 TBMC (g), TBMD (g/m 2 ), leg BMC and BMD, lumbar spine 
BMD, fat mass (FM) and lean tissue mass (LTM) were measured 
using dual-energy X-ray absorptiometry (DXA equipped with pe-
diatric software; Lunar Corp., Madison, Wisc., USA), as previous-
ly reported  [14, 19] , and assessed by the same blinded reader. The 
second, third, and fourth lumbar vertebrae were scanned by antero-
posterior projection (AP-BMD). Only the third lumbar vertebra 
was also measured by lateral scan (L-BMD) because of possible in-
terference with the assessment of the second and fourth lumbar 
vertebrae by overlying ribs or iliac crests, respectively. True volu-
metric BMD (vBMD) was calculated, expressed in g/cm 3 , taking 
the vertebral body as an ellipsoid cylinder and dividing BMC ob-
tained by lateral scan (g) by the body vertebral volume (cm 3 ), cal-
culated as:    ! width/2  ! depth  ! height, to reduce the confound-
ing effect of bone size  [20] . Vertebral dimensions (anterior width, 
depth, and height) were obtained using software data. DXA was 
calibrated daily using a commercial phantom to exclude measure-
ments drifts during the study period. The CVs for duplicate mea-
surements in normal children at an interval of 1 week were 1% for 
AP-BMD, 1.2%  L -BMD, and 2.8% vBMD. The CVs were 0.6% for 
TBMC, 1.0% for TBMD, 1.2% for leg BMC, 1.3 for leg BMD and 
2.2% for FM and LTM. 
 Height, weight and BMI standard deviation scores (SDs) were 
calculated as: (measured value – mean population value)/SD of the 
normal population. 
 TBMC, TBMD, leg BMC and BMD and lumbar spine BMD 
were correlated with FM and total and leg LTM by multiple regres-
sion analysis controlling for age and sex, using bone parameters as 
the dependent variables. 
 Statistical Analysis 
 Descriptive analyses are expressed as mean  8 SD. Statistical 
analyses were performed using unpaired t test, ANOVA, and mul-
tiple regression analysis. All statistical analyses were performed 
using a data analysis system (StatView 4.5; Abacus Concepts, Inc., 
Berkeley, Calif., USA) run on an Apple PowerMac Computer (Ap-
ple Computer, Inc., Cupertino, Calif., USA). Statistical signiﬁ cance 
was set at p  ! 0.05. 
 Results 
 Table 1 shows clinical data of the two groups of pa-
tients at the start of the study and after 1 and 2 years of 
treatment. The two groups of patients were comparable 
for sex, CA, BA, height, height velocity, weight and 
BMI, at the start and after 1 and 2 years of treatment. 
The patients studied were all prepubertal even after 2 
years of treatment. At the start of treatment, BA, height 
and height velocity were signiﬁ cantly lower in the two 
groups of patients than in controls (p  ! 0.05). In both 
groups of patients, height and height velocity rate sig-
niﬁ cantly increased after 1 and 2 years of treatment in 
comparison to pretreatment values (p  ! 0.05 for both 
parameters and for both groups). In both groups of pa-
tients, BMI was slightly higher at the start of the study 
than in controls and slightly decreased after 2 years of 
treatment, but the differences were not statistically sig-
niﬁ cant. 
 There were no differences in physical activity or expo-
sure to sunlight between the two groups of patients, as 
reported in each patient’s exercise diary. Only during the 
second year of treatment was the physical activity slight-
ly higher in boys than in girls (mean 8.1 vs. 7.4 h/week), 
but the difference was not statistically signiﬁ cant. Con-
cerning calcium intake, at the start of treatment it was 
comparable in the two groups of patients (887  8 54 mg/
day in group A and 864  8 39 mg/day in group B) and in 
controls (855  8 43 mg/day). Thereafter, calcium intake 
was comparable only in patients of group A (895  8 
48 mg/day after 1 year; 901  8 36 mg/day after 2 years of 
treatment) and in controls of the same CA (870  8 37 and 
888  8 57 mg/day, respectively). The compliance of cal-
cium supplementation in patients of group B was more 
than 91% in the ﬁ rst year and more than 88% in the sec-
ond year. In fact, calcium intake in group B was 1,645  8 
152 mg/day during the ﬁ rst year of calcium supplementa-
tion and 1,562  8 171 mg/day during the second year, as 
reported in each patient’s food diary. 
 Table 2 shows densitometric data in the two groups of 
patients studied, at the start of therapy and after 1 and 2 
years of treatment. At the start of treatment, TBMC, 
TBMD, leg BMC and BMD, and lumbar BMD were sig-
niﬁ cantly lower in both groups of patients than in controls 
(p  ! 0.05 for all parameters). During the 2 years of the 
study, TBMC, TBMD, and leg BMC and BMD increased 
in patients of both groups and in controls of the same CA. 
After 2 years of treatment, TBMC, TBMD and leg BMC 
and BMD were found to be signiﬁ cantly higher in the 
calcium-supplemented group B than in the unsupple-
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 Table 1. Auxological data of the patients studied at the start and after 1 and 2 years of treatment 
Start 1 year 2 years
controls 
(n = 26)
group A group B controls 
(n = 24)
group A group B controls 
(n = 28)
group A group B
CA, years 8.3081.22 8.2581.50
  (5.0–9.9)
8.2181.41 
  (5.1–9.8)
9.2581.14 9.2281.51
  (6.0–10.9)
9.2181.41
  (6.1–10.8)
10.3381.08 10.2481.49
 (7.1–11.9)
10.2381.42
 (7.1–11.7)
BA, years 8.481.2 6.381.4a 6.281.3a 9.281.3 7.381.4a 7.481.4a 10.381.4 8.681.3a 8.781.2a
Height, cm 128.586.5 113.087.9a 112.886.6a 134.286.1 120.687.8b 121.286.6b 139.486.3 128.088.1b 128.386.8b
Height, SDs 0.3180.37 –2.5180.34a –2.5380.36a 0.2380.28 –1.9880.32b –1.9580.29b 0.3385.72 –1.4980.25b –1.4680.17b
 height SDs/years 0.5480.27 0.5980.30 0.5080.32 0.5280.28
Height velocity, cm/year 6.5581.26* 3.6680.50*, a 3.6280.52*, a 5.8381.80* 7.7380.73b 8.1681.01b 5.6881.92* 7.3681.11b 7.2081.09b
Weight, kg 27.582.6 22.482.8 22.683.0 30.282.9 25.183.15 25.683.19 32.883.42 28.183.87 28.384.07
Weight, SDs 0.1280.48 –1.1480.46 –1.0680.54 0.0580.38 –0.9880.44 –0.8980.46 0.3380.35 –0.5880.43 –0.5580.42
BMI, kg/m2 16.780.8 17.581.0 17.881.2 16.880.79 17.381.03 17.581.17 16.980.98 17.181.12 17.281.11
BMI, SDs 0.2580.13 0.4280.12 0.4680.14 0.2880.18 0.4080.15 0.5180.13 0.2080.19 0.2380.18 0.2580.22
Group A: patients treated solely with hGH. Group B: patients treated with hGH and supplemented with calcium. All data are expressed as mean 8 SD.
CA = Chronological age; BA = bone age; BMI = body mass index.
* During the previous 12 months; a vs. controls: p < 0.05; b vs. pretreatment: p < 0.05.
 
 
 Table 2. Densitometric data of the patients studied, at the start and after 1 and 2 years of treatment 
Start 1 year 2 years
controls group A group B controls group A group B controls group A group B
TBMC, g 889.0878.5 827.58135.0c 832.78123.2c 924.4883.3 876.18141.2c
(5.9)
901.28150.6
(8.1)
971.8887.0 908.98147.3
(9.9)
947.28162.2a
(13.7)
TBMC, SDs –0.7980.57 –0.7380.54 –0.5880.62 –0.2880.55 –0.7280.61 –0.2880.56
TBMD, g/cm2 0.84680.39 0.81080.033c 0.81580.027c 0.86880.048 0.83280.039
(2.7)
0.84980.032
(4.1)
0.88980.050 0.85780.037
(5.8)
0.88680.035a
(8.7)
TBMD, SDs –0.9280.56 –0.7980.48 –0.7580.61 –0.4080.48 –0.6480.52 –0.0680.45
Leg BMC, g 266.7822.1 243.1826.4c 245.6824.5c 279.3828.3 254.0827.5c
(4.5)
267.9833.6
(9.4)
294.6833.2 268.8834.5
(10.7)
288.2821.5a
(17.5)
Leg BMC, SDs –1.0580.44 –0.9580.53 –0.8980.62 –0.3980.59 –0.7680.50 –0.1880.49
Leg BMD, g/cm2 0.86180.034 0.79580.033c 0.80080.027c 0.87880.042 0.82380.038
(3.5)
0.84580.032
(5.6)
0.89580.044 0.85180.036
(7.0)
0.89880.034a
(12.2)
Leg BMD, SDs –1.9481.02 –1.7981.11 –1.3180.98 –0.7981.05 –1.0080.79 0.0780.80
Lumbar BMD, g/cm2 0.72080.038 0.67780.048c 0.67380.075c 0.75080.040 0.72280.053
(6.6)
0.72680.075
(7.9)
0.78580.052 0.76480.064
(12.8)
0.78780.090
(16.9)
Lumbar BMD, SDs –1.1380.67 –1.2480.70 –0.7080.65 –0.6080.68 –0.5080.79 0.0580.85
vBMD L3, g/cm3 0.22080.029 0.20480.042 0.20280.034 0.23580.031 0.21780.043
(6.3)
0.21980.032
(8.4)
0.24980.034 0.23280.041
(13.7)
0.24080.031
(18.8)
vBMD L3, SDs –0.5580.38 –0.6280.40 –0.5880.43 –0.5280.66 –0.5080.55 –0.2680.50
FM, % 15.485.7 20.786.0c 19.785.3c 16.084.9 17.987.0
(–13.5)
17.286.4
(–12.7)
15.884.7 16.785.2b
(–19.3)
16.384.6b
(–17.3)
FM, % (SDs) 0.9380.60 0.7580.57 0.3980.49 0.2480.51 0.1980.44 0.1180.47
FM, kg 4.280.8 4.680.9 4.580.7 4.880.9 4.580.6
(–2.2)
4.480.5
(–2.2)
5.281.0 4.880.8
(4.3)
4.580.7
(0.0)
FM, kg (SDs) 0.5080.30 0.3880.33 –0.3380.29 –0.4480.30 –0.4080.28 –0.7080.39
Total LTM, % 81.484.2 75.683.9c 76.684.4c 80.984.7 78.683.6
(3.9)
79.384.1
(3.5)
81.284.0 79.983.8b
(5.7)
80.584.2b
(5.1)
Total LTM, % (SDs) –1.3880.69 –1.1480.75 –0.4980.62 –0.3480.70 –0.3280.55 –0.1880.52
Total LTM, kg 22.481.8 16.981.5c 17.181.6c 24.481.9 19.781.9c
(16.6)
20.381.7c
(18.7)
26.782.1 22.381.8b
(31.9)
22.981.9b
(33.9)
Total LTM, kg (SDs) –3.0681.18 –2.9481.09 –2.4781.11 –2.1681.20 –2.1080.79 –1.8180.70
Leg LTM, kg 7.181.6 5.181.0c 5.280.9c 7.781.9 5.981.2c
(15.7)
6.181.1c
(17.3)
8.581.8 6.781.2b
(31.4)
7.081.2b
(34.6)
Leg LTM, kg (SDs) –1.2580.98 –1.1980.85 –0.9580.71 –0.8480.73 –1.0080.56 –0.8380.69
Group A: patients treated solely with hGH. Group B: patients treated with hGH and supplemented with calcium. All data are expressed as mean 8 SD. 
Percentage variation versus baseline (%) in parentheses.
TBMC = Total bone mineral content; TBMD = total bone mineral density; FM = fat mass; LTM = lean tissue mass. a p < 0.05 vs. group A; b p < 0.05 vs. base-
line; c p < 0.05 vs. controls. The percentage variation (%) in the measured parameters was calculated as: [(measured value – initial value)/initial value] ! 100.
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mented group A (p  ! 0.05, for all these parameters). Lum-
bar BMD and vBMD of the third lumbar vertebra slight-
ly increased, and were not signiﬁ cantly different in the 
two groups of patients.  Figure 1 shows percentage varia-
tion versus baseline for densitometric data of the patients 
studied, at the start and after 1 and 2 years of treat-
ment. 
 At the start of therapy, in both groups of patients 
percentage body FM was signiﬁ cantly higher and total 
and leg LTM signiﬁ cantly lower than in controls (p  ! 0.05 
for each parameter). Thereafter, FM decreased and 
LTM increased and after 2 years of treatment their dif-
ference versus baseline values was statistically signiﬁ cant 
(p  ! 0.05 for both parameters). After 1 year of therapy, 
TBMC, TBMD and leg BMC and BMD were positive-
ly correlated with LTM in both groups of patients (p  ! 
0.05 for each bone parameter). After 2 years of treatment 
( ﬁ g. 2 ), leg BMC and BMD were more positively cor-
related with regional leg LTM in patients of group B 
(r = 0.834 and r = 0.827, respectively; p  ! 0.001) than in 
patients of group A (r = 0.617 and r = 0.637, respectively; 
p  ! 0.05). 
 Table 3 shows bone marker data of the patients stud-
ied, at the start and after 1 and 2 years of treatment. 
Blood 25-OHD and PTH levels were in the normal range 
and comparable in the two groups of patients and in con-
trols at the start of the study and after 1 and 2 years. Cre-
atinine excretion was not modiﬁ ed by GH treatment. 
Urine Ca/Cr ratio was comparable in the two groups of 
patients and in controls at the start of the study and after 
treatment. Serum OC levels were signiﬁ cantly lower and 
urinary NTx levels signiﬁ cantly higher in patients than 
in controls (p  ! 0.05 for both parameters, either at the 
start or after 1 year of treatment). After 2 years of treat-
ment, OC levels were signiﬁ cantly higher than at the 
start of the study (p  ! 0.05) in both groups of patients; 
but they were signiﬁ cantly higher in group B than in 
group A (p  ! 0.05); on the contrary, urinary NTx levels 
were signiﬁ cantly lower in group B than in group A 
(p  ! 0.05). 
 Fig. 1. Percentage variation versus baseline (  %) for densitometric 
data of the patients studied, after 1 and 2 years of treatment. Group 
A: patients treated solely with hGH (grey columns); group B: pa-
tients treated with hGH and supplemented with calcium (black 
columns). * p  ! 0.05 vs. group A. 
 Fig. 2. Correlation between leg BMC and BMD and regional leg 
tissue mass (LTM) in patients treated solely with hGH (group 
A – white circles) and in patients treated with hGH and supple-
mented with calcium (group B – black circles), after 2 years of treat-
ment. Regression analysis shows leg BMC (1) and BMD (2) more 
positively correlated with regional leg LTM in patients of group B 
than in patients of group A.  a Group A: r = 0.617; p  ! 0.05. Group 
B: r = 0.834; p  ! 0.01.  b Group A: r = 0.637; p  ! 0.05. Group B: 
r = 0.827; p  ! 0.01. 
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 Discussion 
 GH and IGFs with synergic actions control growth, 
increase muscle mass and affect mineralization of the 
skeleton  [21] . In fact, GH deﬁ ciency is associated with 
decreased bone density in growing children  [22] . 
 GH replacement improves BMD in children  [22, 23] , 
supporting a physiologic role for GH in increasing the rate 
of linear growth and bone maturation and in acquisition 
of bone mass, thus improving ﬁ nal adult height and PBM 
achievement  [21, 24] . PBM, which can be deﬁ ned as the 
amount of bone tissue present at the time of skeletal mat-
uration, is an important determinant for osteoporosis and 
fracture risks in later life. 
 BMD increases with age and is age-dependent  [25] and 
about half of adult PBM is accumulated during the ado-
lescent growth spurt. The magnitude of the PBM achieved 
during adolescence depends on genetic-ethnic and envi-
ronmental factors as physical activity and muscle strength. 
Also body composition  [26] and previous nutrition, espe-
cially if calcium-supplemented  [9, 10, 25] , are impor-
tant. 
 It has been demonstrated in the past  [9, 25] that cal-
cium supplementation enhanced the rate of increase in 
total body BMD in prepubertal children. Our data agree 
with the inﬂ uence of calcium quantity in the diet for the 
acquisition of adequate bone mass. In fact, in our calci-
um-supplemented GHD patients of group B, BMC and 
BMD were signiﬁ cantly higher after 2 years of treatment 
than in patients of group A, treated with solely GH. BMC 
and BMD increase was evident at the legs, but not at the 
lumbar spine. 
 The mechanism by which oral calcium increases BMC 
and BMD remains speculative. However, it is well known 
that PTH and GH are important regulators, the ﬁ rst of 
bone remodeling and the second of PTH secretion and 
target-organ action. Recently, it has been demonstrated 
that GHD adults, in whom reduced PTH target-organ 
sensitivity exists, showed after GH replacement therapy 
PTH decrease, suggesting an improvement in PTH sen-
sitivity  [27] . In our study, PTH level tended to increase 
in the unsupplemented group A and to decrease in the 
calcium-supplemented group B. In this latter group, cal-
cium elimination, as demonstrated by urine Ca/Cr ratio 
along the period of GH treatment, showed a trend to de-
crease, in spite of higher calcium intake. Even if not sta-
tistically signiﬁ cant, the behavior of PTH variation and 
of calcium elimination in group B may be suggestive of a 
synergistic effect of GH treatment and calcium supple-
mentation on PTH sensitivity and of better calcium re-
pletion. On the other hand, the variations of bone mark-
ers during GH therapy reﬂ ected those of bone turnover. 
 Table 3. Bone marker data of the patients studied, at the start and after 1 and 2 years of treatment  
Start 1 year 2 years
controls group A group B controls group A group B controls group A group B
25-OHD, nmol/l 58813 62815 57812 61817 64819
(+3.2)
59815
(–3.5)
49813 60818
(–3.2)
56814
(–1.7)
25-OHD, SDs 0.3180.95 –0.0880.89 0.1780.78 –0.1280.87 0.8580.94 0.5480.76
PTH, pmol/l 2.880.7 2.680.6 2.980.8 3.181.1 2.981.0
(+11.5)
2.680.9
(–10.3)
3.481.2 3.181.0
(+18.2)
2.781.1
(–6.9)
PTH, SDs –0.2980.58 0.1480.65 –0.1880.70 –0.4580.80 –0.2580.77 –0.5880.93
Oc, nmol/l 3.1380.72 1.4180.33c 1.5880.43c 3.4980.82 2.5680.40b
(+81.5)
2.6880.48b
(+69.6)
3.6980.68 2.4780.41b
(+75.2)
3.0180.55a, b
(+90.5)
Oc, SDs –2.3981.13 –2.1581.31 –1.1381.03 –0.9981.02 –1.7980.78 –1.0080.67
uNTx, nmol BCE/
mmol creatinine 3458110 6388145c 5818156c 3868123 5618167c
(–12.7)
5348145c
(–8.1)
3788125 7028174c
(+10.3)
5308132a, c
(–8.8)
uNTx, SDs 2.6681.20 2.1681.18 1.4280.58 1.2080.49 2.5981.14 1.2280.82
uCa/Cr, mol/mmol 242878 244882 242873 240885 243888
(–0.4)
241875
(–0.4)
237890 243879
(–0.4)
238890
(–1.24)
uCa/Cr, SDs 0.0380.88 –0.0080.76 0.0480.83 0.0180.90 0.0780.81 0.0180.79
Group A: patients treated solely with hGH. Group B: patients treated with hGH and supplemented with calcium. All data are expressed as mean 8 SD. 
Percentage variation versus baseline (%) in parentheses.
25-OHD = 25-Hydroxyvitamin D; PTH = parathyroid hormone; Oc = osteocalcin; NTx = n-terminal telopeptide of type I collagen; Ca/Cr = calcium/cre-
atinine. a p < 0.05 vs. group A; b p < 0.05 vs. baseline; c p < 0.05 vs. controls. The percentage variation (%) in the measured parameters was calculated as: 
[(measured value – initial value)/initial value] !100.
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OC levels were lower in patients than in controls at the 
start of treatment; the low levels of this bone formation 
marker testiﬁ ed in patients a reduction in osteoblastic 
activity and a failure of accretion of bone mass. OC levels 
increased after GH therapy as consequence of bone re-
modeling stimulation, but after 2 years of treatment they 
were signiﬁ cantly higher in patients supplemented with 
calcium, testifying a greater apposition of calcium in 
bones. The behavior of the levels of urinary NTx, marker 
of bone resorption, was inverse. 
 Furthermore, since in growing normal children usual 
calcium intake may not result in maximal mineral reten-
tion, we could speculate that in treated GHD children 
calcium supplementation at the beginning of GH treat-
ment could aid in reaching a major mineral retention, 
that is particularly evident in those areas of the body that, 
by means of GH treatment, reach a greater muscle mass 
and need of a greater bone strength. Therefore, the thera-
peutic association of GH and calcium could represent a 
valuable tool in pursuing, besides the ﬁ nal target height, 
also a proper BMC in GHD patients. 
 Physical activity is among the factors that promote 
greater bone density in children and adolescents  [28, 29] 
and it has been positively correlated with the lumbar 
spine or femoral neck BMD  [20, 25] . However, all our 
patients, calcium supplemented or not, carried out the 
same physical activity and did not show differences in 
lumbar BMD. 
 It is well known that, besides growth and bone miner-
alization, GH affects body composition  [21] . In fact, at 
the start of treatment, our GHD patients showed in-
creased FM and decreased LTM. During GH substitutive 
therapy FM decreased and LTM increased and this was 
conﬁ rmed by the constant values of BMI, in spite of the 
weight’s increase  [30] . An association of LTM and FM 
with BMC in children has been demonstrated in the past 
 [26] , and more recently it has been stressed the relation-
ship between BMC and LTM using DXA and the impor-
tance of LTM in the interpretation of DXA  [29, 31, 32] . 
After 2 years of treatment, in our calcium-supplemented 
patients of group B, leg BMC and BMD were more posi-
tively correlated with regional leg LTM than in the un-
supplemented patients of group A. Potential mechanisms 
for this positive association include the mechanical load 
and force placed on bone by increased LTM and related 
skeletal muscles attached to bone  [29] . On the other hand, 
lean body mass reﬂ ects skeletal muscle mass and bone 
and skeletal muscle form an operational unit. As muscle 
action delivers the largest loads and bone strains, the chil-
dren with greater muscle mass have a greater BMC  [31, 
33] . So, bone mass is associated with muscle mass and 
increase of muscle mass is important for the attainment 
of PBM  [34] . Both GH and calcium, affecting muscle 
mass and inﬂ uencing bone cells, could contribute to great-
er leg bone mass. On the other hand, previous studies 
showed that the highest contribution of lean mass to BMC 
was observed at the legs  [35] , and that calcium supple-
mentation in prepubertal subjects induced a skeletal site 
selectivity with a greater BMD in the appendicular skel-
etal sites  [10, 36] , suggesting an appendicular skeleton 
more sensitive than the axial skeleton to the effect of cal-
cium supplementation. It will be interesting to discover, 
continuing in future our study, if calcium supplementa-
tion in childhood will be important in maintaining its 
beneﬁ ts also in young adults with discontinued GH treat-
ment. 
 It is frequently stressed that various factors can cause 
misinterpretation of DXA bone measures in children. 
Some strategies have been proposed  [34] to decrease the 
inﬂ uence of growth on the DXA BMD, taking into ac-
count various anthropometric parameters to adjust for 
the inﬂ uence of body and skeletal growth and develop-
ment on BMD values. However, these adjustments add 
great complexity to the pediatric bone studies. On the 
other hand, it has been recently suggested that DXA BMC 
is a more reliable measure than DXA BMD for assessing 
bone acquisition in prepubertal children  [34] . Moreover, 
the two groups of our patients were all prepubertal, even 
at the ﬁ nal evaluation, and comparable for CA, BA, 
height, weight and BMI.  
 In conclusion, in our GHD children treated with recom-
binant GH, bone densitometric parameters improved, 
however the group of GHD children supplemented with 
calcium showed a better BMC and BMD. Calcium supple-
mentation could aid in protecting weight-bearing bones, 
usually completed in childhood to maximum levels, from 
risk of osteoporosis and fractures later in life, and in reach-
ing better PBM achievement. 
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